Evidence map›Paper›PMID 40811471›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Therapeutic CD8

M Betina Pampena, Sadia Samer, Elise G Viox, Kevin Nguyen, Claire Deleage, Leticia Kuri-Cervantes, James Regan, Vincent H Wu, Steffen Docken, Jeffrey T Safrit and 5 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

M Betina Pampena *Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0001-6665-4865
Sadia Samer *Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329.
Elise G VioxDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329.
Kevin NguyenDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329.
Claire DeleageAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21701.
Leticia Kuri-CervantesDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-2432-9500
James ReganDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Vincent H WuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Steffen DockenInfection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, NSW 2033, Australia.ORCID 0000-0003-3771-5504
Jeffrey T SafritImmunityBio, Inc., Culver City, CA 90245.
Katharine J BarDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21701.ORCID 0000-0002-2381-1151
Miles P DavenportInfection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, NSW 2033, Australia.ORCID 0000-0002-4751-1831
Mirko PaiardiniDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329.
Michael R BettsDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-7690-1484

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Viral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Joyce Kimberly Cohen · 2018 to 2026
$17.5M
Project 2 - Michael BettsP01AI131338 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BETTS, MICHAEL R · 2017 to 2021
$7.8M
HHS | NIH | National Cancer Institute (NCI) 75N91019D00024/HHSN261201500003IHHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P01AI131338HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P51OD011132HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U42OD011023HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI126620HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI164562NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INIAID NIH HHS P01 AI131338NIAID NIH HHS P30 AI045008NIAID NIH HHS P30 AI050409NIAID NIH HHS UM1 AI126620NIAID NIH HHS UM1 AI164562NIH HHS P51 OD011132NIH HHS U42 OD011023Tissue Reservoirs Scientific Working Group in the Penn Center for AIDS Research P30 AI 045008
6 · The paper itself

Abstract

A primary obstacle for HIV elimination is the long-term viral reservoir in lymphoid tissues (LT) that can cause rebound viremia if therapy is stopped. Cytotoxic CD8

Indexed as

Anti-Retroviral AgentsCD8-Positive T-LymphocytesImmunomodulationSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsCD4-Positive T-LymphocytesFingolimod HydrochlorideLymphoid TissueMacaca mulattaViral LoadViremiaVirus ReplicationAnti-Retroviral AgentsFingolimod HydrochlorideARTCD8+ T cellsimmunomodulationlymph nodesSIV

Identifiers

PMID40811471
PMCPMC12377730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.